Drug recall · June 5, 2024
Cefdinir for Oral Suspension USP recall
Why: Defective container: lack of seal integrity.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, Manufactured by: Lupin Limited, Mandideep, 462 046 India, NDC 68180-723-04
- Lots / codes
Lot #F305184, F305185, F305186, Exp 7/31/ 2025
- Quantity
- 51,006 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- USA Nationwide
- Initiated
- May 8, 2024 · Voluntary: Firm initiated
- Classified
- May 29, 2024
- Reported
- June 5, 2024
- Ended
- April 29, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefdinir
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.